Vaccines for preventing malaria (Q24250252)

27 June 2017

0 references

1 reference

title

Vaccines for preventing malaria (English)

1 reference

27 June 2017

0 references

1 reference

1 reference

P Graves

1

0 references

Patricia M. Graves

series ordinal

1

1 reference

27 June 2017

H Gelband

2

1 reference

PubMed ID

12535387

27 June 2017

language of work or name

English

0 references

publication date

20 January 2003

0 references

1 January 2003

1 reference

PubMed ID

12535387

Cochrane Database of Systematic Reviews

27 June 2017

2000

0 references

published in

1 reference

27 June 2017

CD000129

1 reference

27 June 2017

1

1 reference

PubMed ID

12535387

Safety evaluation of SPf66 malaria vaccine in Brazil

27 June 2017

2

0 references

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000129

SPf66 vaccine trial in Brazil: conceptual framework study design and analytical approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000129

Duration of protection and age-dependence of the effects of the SPf66 malaria vaccine in African children exposed to intense transmission of Plasmodium falciparum

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000129

Safety, immunogenicity, and efficacy of Plasmodium falciparum repeatless circumsporozoite protein vaccine encapsulated in liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000129

A totally synthetic polyoxime malaria vaccine containing Plasmodium falciparum B cell and universal T cell epitopes elicits immune responses in volunteers of diverse HLA types

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000129

Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000129

A population-based clinical trial with the SPf66 synthetic Plasmodium falciparum malaria vaccine in Venezuela

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000129

Vaccination with SPf66, a chemically synthesised vaccine, against Plasmodium falciparum malaria in Colombia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000129

7 January 2021

Study of the safety and immunogenicity of the synthetic malaria SPf66 vaccine in children aged 1-14 years

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000129

7 January 2021

The first field trials of the chemically synthesized malaria vaccine SPf66: safety, immunogenicity and protectivity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000129

7 January 2021

Safety, immunogenicity and limited efficacy study of a recombinant Plasmodium falciparum circumsporozoite vaccine in Thai soldiers.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000129

7 January 2021

A trial of the synthetic malaria vaccine SPf66 in Tanzania: rationale and design

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000129

7 January 2021

Safety, immunogenicity and protective effect of the SPf66 malaria synthetic vaccine against Plasmodium falciparum infection in a randomized double-blind placebo-controlled field trial in an endemic area of Ecuador

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000129

7 January 2021

Plasmodium falciparum circumsporozoite vaccine immunogenicity and efficacy trial with natural challenge quantitation in an area of endemic human malaria of Kenya

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000129

7 January 2021

SPf66 malaria vaccine is safe and immunogenic in malaria naive adults in Thailand.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000129

7 January 2021

Reduction in the mean number of Plasmodium falciparum genotypes in Gambian children immunized with the malaria vaccine SPf66.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000129

7 January 2021

Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000129

7 January 2021

Malaria vaccines: are seven antigens better than one?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000129

7 January 2021

Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000129

7 January 2021

Efficacy trial of malaria vaccine SPf66 in Gambian infants

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000129

7 January 2021

Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Shoklo SPf66 Malaria Vaccine Trial Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000129

7 January 2021

The SPf66 Malaria Vaccine: What is the Evidence for Efficacy?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000129

7 January 2021

Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000129

7 January 2021

Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000129

7 January 2021

Evaluation of SPf66 malaria vaccine during a 22-month follow-up field trial in the Pacific coast of Colombia.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000129

7 January 2021

An efficacy trial of the malaria vaccine SPf66 in Gambian infants--second year of follow-up.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000129

7 January 2021

Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000129

7 January 2021

Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000129

7 January 2021

Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000129

7 January 2021

Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000129

7 January 2021

Field trials of an asexual blood stage malaria vaccine: studies of the synthetic peptide polymer SPf66 in Thailand and the analytic plan for a phase IIb efficacy study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000129

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD000129

1 reference

7 January 2021

Progress and challenges for malaria vaccines

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000129

7 January 2021

Follow-up of Gambian children recruited to a pilot safety and immunogenicity study of the malaria vaccine SPf66.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000129

7 January 2021

Immune responses to Plasmodium falciparum antigens during a malaria vaccine trial in Tanzanian children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000129

7 January 2021

Evaluation of the SPf66 vaccine for malaria control when delivered through the EPI scheme in Tanzania

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000129

7 January 2021

Safety in infants of SPf66, a synthetic malaria vaccine, delivered alongside the EPI.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000129

7 January 2021

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000129

7 January 2021

A malaria vaccine based on a sporozoite antigen.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000129

7 January 2021

Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccinees of defined HLA genotypes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000129

7 January 2021

Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000129

7 January 2021

A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000129

7 January 2021

Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000129

7 January 2021

Analysis of multiple Plasmodium falciparum infections in Tanzanian children during the phase III trial of the malaria vaccine SPf66.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000129

7 January 2021

Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000129

7 January 2021

Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000129

7 January 2021

Antibody and clinical responses in volunteers to immunization with malaria peptide-diptheria toxoid conjugates.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000129

7 January 2021

A pilot safety and immunogenicity study of the malaria vaccine SPf66 in Gambian infants.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000129

7 January 2021

Safety, immunogenicity, and efficacy of a malaria sporozoite vaccine administered with monophosphoryl lipid A, cell wall skeleton of mycobacteria, and squalane as adjuvant

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000129

7 January 2021

Safety, immunogenicity, and pilot efficacy of Plasmodium falciparum sporozoite and asexual blood-stage combination vaccine in Swiss adults.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000129

7 January 2021

Phase I safety and immunogenicity testing of clinical lots of the synthetic Plasmodium falciparum vaccine SPf66 produced under good manufacturing procedure conditions in the United States.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000129

7 January 2021

Phase I trial of the SPf66 malaria vaccine in a malaria-experienced population in Southeast Asia.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000129

7 January 2021

Evaluation of SPf66 malaria vaccine efficacy in Brazil.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000129

7 January 2021

Immunization with SPf66 and subsequent infection with homologous and heterologous Plasmodium falciparum parasites.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000129

7 January 2021

A phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in The Gambia.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000129

7 January 2021

10.1002/14651858.CD000129

Identifiers

DOI

1 reference

27 June 2017

1 reference